Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Minimal residual disease assessment in colorectal cancer (MiRDA-C).
Authors
Arvind Dasari
University of Texas MD Anderson Cancer Center, Houston, TX
Arvind Dasari , Maen Abdelrahim , Jared David Acoba , Krishna Chaitanya Alluri , Tomislav Dragovich , Syed Mohammad Ali Kazmi , Benjamin Leon Musher , Ryan Sun , Lucas Wong , Y. Nancy You , Robert Anthony Zaiden , Scott Kopetz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT04739072
DOI
10.1200/JCO.2022.40.4_suppl.TPS236
Abstract #
TPS236
Poster Bd #
P5
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program.
First Author: Arvind Dasari
Poster
2024 ASCO Gastrointestinal Cancers Symposium
INTERCEPT Program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): Results from a prospective clinical cohort.
First Author: Giulia Maddalena
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy: Results from the MD Anderson INTERCEPT Program.
First Author: Andrew Jared Pellatt
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Circulating tumor DNA (ctDNA) informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers.
First Author: Rutika Mehta